Growth rides on sensors, but margins are thinner
- Fiscal 2026 net sales were $3.1 billion, up 14%, led by international growth.
- International sales were 70% of fiscal 2026 revenue and grew much faster than the U.S.
- The main profit engine is a base of pumps that drives repeat sales of sensors, infusion sets, and reservoirs.
- MiniMed Flex and MiniMed Go give the company new ways to win users, but both still need proof in the market.
- The bear case is pricing pressure in CGM, stand-alone costs after the IPO, and lower margins as sensors become a bigger mix.
Sensors lift growth, margins test it
MiniMed is a diabetes device company with a real installed base. Its flagship MiniMed 780G system combines an insulin pump, a CGM, which means continuous glucose monitor, and software that helps dose insulin. That base matters because many users keep buying single-use sensors and supplies after the first pump sale.
The bull case starts outside the U.S. International sales grew 21% in fiscal 2026, while U.S. sales grew 2%. Global CGM Attachment Rate rose to 66% from 59%, which means more pump users are also using MiniMed sensors. That creates more recurring revenue per user.
New products could add another leg. MiniMed Flex, a smartphone-controlled pump, launched in the U.S. in June 2026 after FDA clearance. MiniMed Go, the Smart MDI system for people using multiple daily injections, launched in Europe in February 2026 and in the U.S. in May 2026. MiniMed also extended its Abbott partnership for dual glucose-ketone sensors, though those sensors are still under development.
The bear case is not about demand alone. CGMs carry lower profit margins than pumps and other consumables, and the pharmacy channel is more rebate-heavy. The company is also newly public after a Medtronic carve-out, with Medtronic still owning about 90% of the shares. That makes costs, governance, and any future Medtronic divestment key watch points.
A pump base that keeps buying
MiniMed makes money from reusable devices and repeat-use supplies. Pumps and smart insulin pens can stay with a patient for a year or more. Pumps are often replaced every four to five years, depending on payer rules and geography.
The repeat business comes from CGM sensors, infusion sets, and reservoirs. These are single-use products that patients replace often to keep an automated insulin delivery system working. If MiniMed grows its user base and raises sensor attachment, sales can grow even when pump sales are choppy.
There are two weak spots in this model. First, sensors can be lower margin than pumps, so faster CGM growth can pressure gross profit. Second, pharmacy coverage can make CGM pricing tougher because rivals can use rebates to lower patient costs and limit competing coverage.
MiniMed is also still separating from Medtronic. The 2026 financial statements include $298 million of corporate and shared expenses allocated from Medtronic for the fiscal year. Those allocations may not match what MiniMed will spend as a fully stand-alone company.
The diabetes toolkit
MiniMed 780G AID system
This is the flagship automated insulin delivery system. It links a pump, CGM sensor, infusion supplies, and a dosing algorithm.
MiniMed Flex
Flex is a discreet, smartphone-controlled insulin pump. It launched in the U.S. in June 2026 after FDA clearance, but the early clearance also caused some buyers to wait.
CGM sensors
The sensor lineup includes Simplera Sync and Instinct. CGM sales grew 18% in fiscal 2026 as attachment rose across the pump base.
Infusion sets and reservoirs
These consumables keep pump systems running. They are important because they turn a durable pump sale into repeat revenue.
MiniMed Go Smart MDI
MiniMed Go targets people who use multiple daily injections instead of a pump. It launched in Europe in February 2026 and in the U.S. in May 2026.
Abbott dual glucose-ketone sensors
MiniMed and Abbott are working on dual glucose-ketone sensors for MiniMed smart dosing systems. The sensors are still under development and not yet sold.
Mostly international revenue
This mix uses fiscal 2026 net sales by market geography for the year ended April 24, 2026. MiniMed also discloses product categories, but the clearest segment split is U.S. versus International.
What could break the thesis
CGM rebate pressure
High impact · High oddsCGM products are moving into the pharmacy channel, where pricing can be shaped by rebates. MiniMed says rivals have broad pharmacy coverage and can offer enhanced rebates. If MiniMed has to match those rebates, growth could come with weaker margins.
Sensor mix lowers profit
High impact · Medium oddsCGMs are growing faster than pumps, but MiniMed says CGMs have historically carried lower profit margins than insulin pumps and other consumables. That means the fastest-growing product line can still hurt profit rate. The company needs manufacturing scale and premium features to offset this.
Stand-alone cost creep
Medium impact · Medium oddsMiniMed only became a public company in March 2026. It still relies on Medtronic for transition services and manufacturing arrangements. The old carve-out cost base may not show the full cost of being independent.
Pump buyers wait for new models
Medium impact · Medium oddsThe early FDA clearance of MiniMed Flex caused some customers to delay pump purchases in the fourth quarter of fiscal 2026. That shows new launches can pull demand forward or push it out. If Flex adoption is slow, the pause could turn into lost sales.
Balance sheet and accounting shocks
Medium impact · Medium oddsMiniMed recorded a $157 million one-time charge tied to future minimum royalty payment obligations after Flex clearance. The company also carries large goodwill, which can be impaired if the business outlook or stock price weakens. These items may not change device demand, but they can hit reported results.
In one breath
What does MiniMed Group do?
MiniMed makes diabetes devices and supplies. Its systems include insulin pumps, CGM sensors, infusion sets, reservoirs, smart insulin pens, and dosing software.
Why does Medtronic still matter to MMED?
MiniMed used to be Medtronic's diabetes business and became public in March 2026. Medtronic still owns about 90% of the shares and provides transition services, so future divestment and separation costs matter.
What is the biggest growth driver for MiniMed?
The biggest driver is getting more users onto MiniMed systems and selling more CGM sensors to that base. Global CGM Attachment Rate rose to 66% in fiscal 2026, up from 59% the year before.
Why are investors worried about MiniMed margins?
CGMs are growing fast, but they have lower profit margins than pumps and some other supplies. The pharmacy channel can also create tougher pricing because competitors use rebates.